Log in

Relevant bibliographies by topics / Cancer chemotherapies / Journal articles

To see the other types of publications on this topic, follow the link: Cancer chemotherapies.

Journal articles on the topic 'Cancer chemotherapies'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer chemotherapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Villasana, M., and G. Ochoa. "Heuristic Design of Cancer Chemotherapies." IEEE Transactions on Evolutionary Computation 8, no. 6 (2004): 513–21. http://dx.doi.org/10.1109/tevc.2004.834154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ranftler, Matthias, and Kathrin Strasser-Weippl. "New chemotherapies in breast cancer." memo - Magazine of European Medical Oncology 10, no. 3 (2017): 127–31. http://dx.doi.org/10.1007/s12254-017-0348-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Froelich, Warren. "Cardiotoxic Chemotherapies in Young Cancer Survivors." Oncology Times 43, no. 11 (2021): 48. http://dx.doi.org/10.1097/01.cot.0000754744.48767.ee.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chaffer, Christine Louise, Heloisa H. Milioli, Beatriz P. San Juan, Rachel F. Dear, and Jia (Jenny) Liu. "Abstract 4744: State-gating cancer to prevent chemotherapy-resistance." Cancer Research 85, no. 8_Supplement_1 (2025): 4744. https://doi.org/10.1158/1538-7445.am2025-4744.

Full text

Abstract:

Abstract New approaches are urgently required to treat advanced-stage cancers that are therapy resistant and incurable. Furthermore, salvage treatment protocols rely on cytotoxic chemotherapies that actively induce cancer cells to transition into therapy-resistant states via non-genetic mechanisms. We show in large clinical cohorts of triple-negative breast cancer (TNBC) that chemotherapy-induced cell state changes are mediated by androgen receptor (AR) signaling and are associated with poor patient outcome. AR inhibition blocks canonical and non-canonical AR signaling to lock cancer cells in

APA, Harvard, Vancouver, ISO, and other styles

5

Gomes, Ana. "AGE-INDUCED SYSTEMIC REPROGRAMMING DRIVES DRUG RESISTANCE IN LUNG CANCER." Innovation in Aging 7, Supplement_1 (2023): 139–40. http://dx.doi.org/10.1093/geroni/igad104.0457.

Full text

Abstract:

Abstract Lung cancer accounts for the largest number of cancer-associated deaths in the United States. While great strides have been made due to the introduction of immunotherapies and targeted therapies against oncogenic drivers, chemotherapies remain the standard of care for the majority of lung cancer patients. However, many patients do not respond to these treatments or relapse following an initial response. We postulate that part of the problem is the lack of consideration in preclinical research and clinical trials of the main driver of lung tumorigenesis, the aging process. Here, we sho

APA, Harvard, Vancouver, ISO, and other styles

6

He, Ji, Erika Fortunati, Dong-Xu Liu, and Yan Li. "Pleiotropic Roles of ABC Transporters in Breast Cancer." International Journal of Molecular Sciences 22, no. 6 (2021): 3199. http://dx.doi.org/10.3390/ijms22063199.

Full text

Abstract:

Chemotherapeutics are the mainstay treatment for metastatic breast cancers. However, the chemotherapeutic failure caused by multidrug resistance (MDR) remains a pivotal obstacle to effective chemotherapies of breast cancer. Although in vitro evidence suggests that the overexpression of ATP-Binding Cassette (ABC) transporters confers resistance to cytotoxic and molecularly targeted chemotherapies by reducing the intracellular accumulation of active moieties, the clinical trials that target ABCB1 to reverse drug resistance have been disappointing. Nevertheless, studies indicate that ABC transpor

APA, Harvard, Vancouver, ISO, and other styles

7

Fakiruddin, Kamal Shaik, Moon Nian Lim, Norshariza Nordin, Rozita Rosli, and Syahril Abdullah. "Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines." Biology 10, no. 11 (2021): 1103. http://dx.doi.org/10.3390/biology10111103.

Full text

Abstract:

Pre-clinical studies have demonstrated the efficacy of mesenchymal stem cells (MSCs) expressing tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or MSC-TRAIL against several tumors. However, due to the existence of cancer stem cells (CSCs), some tumors, including non-small cell lung cancer (NSCLC), exhibit TRAIL resistance. This study was designed to evaluate the capacity of using first-line chemotherapies including cisplatin, 5-fluorouracil (5-FU) and vinorelbine to act as a chemo-sensitizer on CD133+ (prominin-1 positive) CSCs derived from NSCLC cell lines (A549, H460 an

APA, Harvard, Vancouver, ISO, and other styles

8

Si, Yingnan, Ya Zhang, Hanh Giai Ngo, et al. "Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer." Cancers 13, no. 15 (2021): 3749. http://dx.doi.org/10.3390/cancers13153749.

Full text

Abstract:

Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs. Specifically, the IC50 values of the microtubule polymerization inhibitor mertansine (DM1), mitotic spindle assembly defecting taxane (paclitaxel, PTX), DNA synthesis inhibitor gemcitabine (GC), and DNA damage inducer doxorubicin (A

APA, Harvard, Vancouver, ISO, and other styles

9

Ranieri, Girolamo, and Carmelo Laface. "Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments." Cancers 12, no. 10 (2020): 2737. http://dx.doi.org/10.3390/cancers12102737.

Full text

Abstract:

This Special Issue of Cancers, titled “Loco-Regional Arterial Chemotherapies Alone or in Combination with Systemic Treatments for Primary and Secondary Hepato-Pancreatic Tumors”, focuses on new possible strategies to treat only liver disease (or mainly liver disease) through the combination of loco-regional and systemic chemotherapies [...]

APA, Harvard, Vancouver, ISO, and other styles

10

Herzog, Thomas J., Thomas C. Krivak, John Paul Diaz, et al. "Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial." Journal of Clinical Oncology 42, no. 16_suppl (2024): 5518. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5518.

Full text

Abstract:

5518 Background: Patients with recurrent platinum-resistant epithelial ovarian cancer (EOC) have poor clinical outcomes, owing in large part to the presence of therapy-resistant cancer stem cells (CSCs). A randomized clinical trial (NCT03949283) was conducted to determine if chemotherapy regimens guided by the CSCs functional assay (ChemoID) can improve objective response rate (ORR) in patients with recurrent platinum-resistant EOC when compared to empiric treatment selection. Methods: Patients with recurrent platinum-resistant EOC who had failed standard of care (SOC) therapy, were randomly a

APA, Harvard, Vancouver, ISO, and other styles

11

Dima, Augustin Catalin, Alina Dima, Sever Calin Moldovan, and Mircea Ciurea. "Predictive biomarkers for chemotherapies in pancreatic cancer." Journal of Translational Medicine and Research 20, no. 3 (2015): 142. http://dx.doi.org/10.21614/jtmr-20-3-46.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Smith, Nancy Zeller. "Treating Metastatic Breast Cancer With Systemic Chemotherapies." Clinical Journal of Oncology Nursing 16, no. 2 (2012): E33—E43. http://dx.doi.org/10.1188/12.cjon.e33-e43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ko, Yoo-Joung, and Michael B. Atkins. "Chemotherapies and immunotherapies for metastatic kidney cancer." Current Urology Reports 6, no. 1 (2005): 35–42. http://dx.doi.org/10.1007/s11934-005-0065-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Yadav, Vikramaditya G. "A potential gut punch to gastric cancer." Science Translational Medicine 12, no. 525 (2020): eaba2906. http://dx.doi.org/10.1126/scitranslmed.aba2906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Raizada, Devesh, Stanislav Drapela, Joanne Tejero, Nadir Sarigul, Didem Ilter, and Ana Gomes. "Abstract 2856: Age-induced chronic accumulation of cortisol drives chemotherapy resistance in lung cancer." Cancer Research 83, no. 7_Supplement (2023): 2856. http://dx.doi.org/10.1158/1538-7445.am2023-2856.

Full text

Abstract:

Abstract Lung cancer accounts for the largest number of cancer-associated deaths in the United States. While great strides have been made due to the introduction of immunotherapies and targeted therapies against oncogenic drivers, chemotherapies remain the standard of care for the majority of lung cancer patients. However, many patients do not respond to these treatments or relapse following an initial response. We postulate that part of the problem is the lack of consideration in preclinical research and clinical trials of the main driver of lung tumorigenesis, the aging process. Here, we sho

APA, Harvard, Vancouver, ISO, and other styles

16

Iraqi, Muhammed, Priyanka Bolel, Rhitajit Sarkar, et al. "NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs." International Journal of Molecular Sciences 23, no. 22 (2022): 14054. http://dx.doi.org/10.3390/ijms232214054.

Full text

Abstract:

Lung cancer cells in the tumor microenvironment facilitate immune evasion that leads to failure of conventional chemotherapies, despite provisionally decided on the genetic diagnosis of patients in a clinical setup. The current study follows three lung cancer patients who underwent “personalized” chemotherapeutic intervention. Patient-derived xenografts (PDXs) were subjected to tumor microarray and treatment screening with chemotherapies, either individually or in combination with the peptide R11-NLS-pep8; this peptide targets both membrane-associated and nuclear PCNA. Ex vivo, employing PDX-d

APA, Harvard, Vancouver, ISO, and other styles

17

Xiao, Boya, and Bicheng Wang. "Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic." Diseases & Research 2, no. 1 (2021): 1–4. http://dx.doi.org/10.54457/dr.202201001.

Full text

Abstract:

The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since December 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies of cancer patients were considerably delayed. Up to now, cancer patients throughout the world directly encounter similar obstacles. For patients who have the right to choose chemotherapeutic regimens with different administration routes, oral drugs can be considered to be applied. In this mini-review, oral chemotherapeutic drugs were compared with intravenous drugs in seven types

APA, Harvard, Vancouver, ISO, and other styles

18

Yasukawa, Maya, Stanislav Drapela, Didem Ilter, Mian M. Shahzad, and Ana P. Gomes. "Abstract LB281: HIRA suppression is a mechanism of chemotherapy resistance in ovarian cancer." Cancer Research 83, no. 8_Supplement (2023): LB281. http://dx.doi.org/10.1158/1538-7445.am2023-lb281.

Full text

Abstract:

Abstract Ovarian cancer accounts for the fifth most common cause of cancer death among women, despite being relatively rare. This is in large because majority of cases are diagnosed at advanced stage and frequently recur after primary treatment. Despite numerous efforts to develop effective targeted therapies and immunotherapies for ovarian cancer the standard of care remains chemotherapies. We postulate that part of the problem is the paucity of preclinical research and clinical trials focused on dormant persister ovarian cancer cells that remain after chemotherapy treatments. Emerging eviden

APA, Harvard, Vancouver, ISO, and other styles

19

Mukherji, Reetu, Dipanjan Debnath, Marion L. Hartley, and Marcus S. Noel. "The Role of Immunotherapy in Pancreatic Cancer." Current Oncology 29, no. 10 (2022): 6864–92. http://dx.doi.org/10.3390/curroncol29100541.

Full text

Abstract:

Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding

APA, Harvard, Vancouver, ISO, and other styles

20

Foulon, Arthur, Pierrick Theret, Lise Rodat-Despoix, and Philippe Kischel. "Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment." Cancers 12, no. 9 (2020): 2634. http://dx.doi.org/10.3390/cancers12092634.

Full text

Abstract:

In 2018, about 2.1 million women have been diagnosed with breast cancer worldwide. Treatments include—among others—surgery, chemotherapy, radiotherapy, or endocrine therapy. The current policy of care tends rather at therapeutic de-escalation, and systemic treatment such as chemotherapies alone are not systematically considered as the best option anymore. With recent advances in the understanding of cancer biology, and as a complement to anatomic staging, some biological factors (assessed notably via gene-expression signatures) are taken into account to evaluate the benefit of a chemotherapy r

APA, Harvard, Vancouver, ISO, and other styles

21

Bahl, Amit. "Castration-resistant Prostate Cancer— Chemotherapies and Molecular Targets." Oncology & Hematology Review (US) 09, no. 02 (2013): 90. http://dx.doi.org/10.17925/ohr.2013.09.2.90.

Full text

Abstract:

Castration-resistant prostate cancer (CRPC) has a poor prognosis: current chemotherapeutic approaches ultimately result in resistance and are associated with survival rates of less than 2 years. However, the last decade has seen an expansion in the number of therapeutic options for CRPC and the regulatory approval of several agents, including the chemotherapy drug cabazitaxel and the targeted agents abiraterone acetate, enzalatumide, and denosumab. Novel targeted agents inhibit androgen receptor-mediated signaling, and nonhormonal targets, including apoptosis, signal transduction pathway inhib

APA, Harvard, Vancouver, ISO, and other styles

22

Okuyama, Hiroyuki, Yoshihiro Okita, and Akihito Tsuji. "Salvage Line Chemotherapies in Metastatic Colorectal Cancer Patients." Nippon Daicho Komonbyo Gakkai Zasshi 71, no. 10 (2018): 387–92. http://dx.doi.org/10.3862/jcoloproctology.71.387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Beusterien, K., J. Grinspan, T. Tencer, A. Brufsky, and C. Visovsky. "Patient preferences for chemotherapies used in breast cancer." Journal of Clinical Oncology 29, no. 15_suppl (2011): e19667-e19667. http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e19667.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cameron, Amanda. "Are costly new chemotherapies justified in colorectal cancer?" PharmacoEconomics & Outcomes News 148, no. 1 (1998): 3–5. http://dx.doi.org/10.1007/bf03277368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Winder, Thomas. "Chemotherapies and future directions in metastatic colorectal cancer." memo - Magazine of European Medical Oncology 10, no. 3 (2017): 141–45. http://dx.doi.org/10.1007/s12254-017-0351-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bahl, Amit. "Castration-resistant Prostate Cancer – Chemotherapies and Molecular Targets." European Oncology & Haematology 09, no. 01 (2013): 27. http://dx.doi.org/10.17925/eoh.2013.09.1.27.

Full text

Abstract:

Castration-resistant prostate cancer has a poor prognosis: current chemotherapeutic approaches ultimately result in resistance and are associated with survival rates of less than 2 years. However, the last decade has seen an expansion in the number of therapeutic options for CRPC and the regulatory approval of several agents, including the chemotherapy drug cabazitaxel and the targeted agents abiraterone acetate, enzalatumide and denosumab. Novel targeted agents inhibit androgen receptor-mediated signalling, and non-hormonal targets, including apoptosis, signal transduction pathway inhibitors,

APA, Harvard, Vancouver, ISO, and other styles

27

Feng, Haitao, Jeong-Hun Kang, Song Qi, Akihiro Kishimura, Takeshi Mori, and Yoshiki Katayama. "Preparation of a PEGylated liposome that co-encapsulates l-arginine and doxorubicin to achieve a synergistic anticancer effect." RSC Advances 11, no. 54 (2021): 34101–6. http://dx.doi.org/10.1039/d1ra06514a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Kalis, Joseph A., Simon J. Pence, Robert S. Mancini, Dan S. Zuckerman, and Joseph R. Ineck. "Prevalence of Off-Label Use of Oral Oncolytics at a Community Cancer Center." Journal of Oncology Practice 11, no. 2 (2015): e139-e143. http://dx.doi.org/10.1200/jop.2014.001354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Yang, Yixuan, and Xiaofeng Dai. "Current status of controlled onco-therapies based on metal organic frameworks." RSC Advances 14, no. 18 (2024): 12817–28. http://dx.doi.org/10.1039/d4ra00375f.

Full text

Abstract:

Most MOFs for controllable cancer treatment act as drug delivery vehicle and/or anti-cancer agent. Molecules with anti-cancer roles such as chemotherapies, gases, peptides or nucleic acids can be loaded into MOFs that decompose in cancer cells or in the TME to release its cargoes.

APA, Harvard, Vancouver, ISO, and other styles

30

Yao, Liqin, Gang Jia, Lingeng Lu, and Wenxue Ma. "Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?" Current Oncology 29, no. 7 (2022): 4902–13. http://dx.doi.org/10.3390/curroncol29070389.

Full text

Abstract:

Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-D

APA, Harvard, Vancouver, ISO, and other styles

31

Selander, Katri, Juha Klaper, Nataliia Petruk, Mauricio Ramm, Arja Jukkola, and Eeva-Liisa Eskelinen. "Abstract P4-01-13: Low tumor TLR9 expression results in resistance to growth inhibitory and autophagy responses to common breast cancer treatments." Cancer Research 82, no. 4_Supplement (2022): P4–01–13—P4–01–13. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-01-13.

Full text

Abstract:

Abstract Background: Toll like receptor-9 (TLR9) is an intracellular, innate immune system DNA-receptor, which is widely expressed in cancers. We previously demonstrated that low tumor TLR9 protein expression is associated with poor prognosis among triple negative breast cancer (TNBC) patients. A similar result is now detected also in larger, mRNA expression based datasets (Kmplot.com), which extend our initial observation to basal and luminal B clinical subtypes. The reason for TLR9 association with poor prognosis is not known.Aim: Since poor outcomes in early breast cancer are due to adjuvan

APA, Harvard, Vancouver, ISO, and other styles

32

Yasuda, Tsukasa, Junji Hiraga, Michihiko Narita, Yoshimasa Tanikawa, and Tomoyuki Tsuzuki. "Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient." Case Reports in Hematology 2021 (August 26, 2021): 1–4. http://dx.doi.org/10.1155/2021/9965371.

Full text

Abstract:

The case of a 76-year-old man with multiple primary cancers that were treated with nivolumab is presented. Six years earlier, he was diagnosed with multiple myeloma (MM) and was treated with several chemotherapies. He was also diagnosed with gastric cancer with liver metastasis and primary lung cancer by upper gastrointestinal endoscopy and computed tomography (CT). Nivolumab treatment was given as third-line therapy, and it was effective for gastric and lung cancers. But MM worsened, and the patient died. There is no standard treatment for multiple primary cancers, and the development of effe

APA, Harvard, Vancouver, ISO, and other styles

33

Ranjan, Alok, Sharavan Ramachandran, Nehal Gupta, et al. "Role of Phytochemicals in Cancer Prevention." International Journal of Molecular Sciences 20, no. 20 (2019): 4981. http://dx.doi.org/10.3390/ijms20204981.

Full text

Abstract:

The use of synthetic, natural, or biological agents to minimize the occurrence of cancer in healthy individuals is defined as cancer chemoprevention. Chemopreventive agents inhibit the development of cancer either by impeding DNA damage, which leads to malignancy or by reversing or blocking the division of premalignant cells with DNA damage. The benefit of this approach has been demonstrated in clinical trials of breast, prostate, and colon cancer. The continuous increase in cancer cases, failure of conventional chemotherapies to control cancer, and excessive toxicity of chemotherapies clearly

APA, Harvard, Vancouver, ISO, and other styles

34

Chen, Jinghua, Meiqin Zhu, Liqiu Zou, et al. "Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO." Acta Biochimica et Biophysica Sinica 52, no. 8 (2020): 801–9. http://dx.doi.org/10.1093/abbs/gmaa072.

Full text

Abstract:

Abstract The treatment of triple-negative breast cancer (TNBC) relies largely on chemotherapies. However, it is frequent that TNBC patients develop resistance to the chemotherapy drugs. Generation of drug-resistant cell lines facilitates the identification of drug resistance. Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells. Ectopic expression of LINC-PINT sensit

APA, Harvard, Vancouver, ISO, and other styles

35

Conti, Rena M., Arielle C. Bernstein, Victoria M. Villaflor, Richard L. Schilsky, Meredith B. Rosenthal, and Peter B. Bach. "Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists." Journal of Clinical Oncology 31, no. 9 (2013): 1134–39. http://dx.doi.org/10.1200/jco.2012.42.7252.

Full text

Abstract:

Purpose The prevalence of off-label anticancer drug use is not well characterized. The extent of off-label use is a policy concern because the clinical benefits of such use to patients may not outweigh costs or adverse health outcomes. Methods Prescribing data from IntrinsiQ Intellidose data systems, a pharmacy software provider maintaining a population-based cohort database of medical oncologists, was analyzed. Use of the most commonly prescribed anticancer drugs (“chemotherapies”) that were patent protected and administered intravenously to patients in 2010 was examined. Use was classified a

APA, Harvard, Vancouver, ISO, and other styles

36

Oren, Ohad, and Michal Oren. "Evaluation of cardiovascular status in clinical trials in breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e14038-e14038. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14038.

Full text

Abstract:

e14038 Background: With the expansion of treatment options in oncology, patients are now increasingly exposed to potentially cardio-injurious compounds. Nevertheless, many clinical trials do not assess the cardiac status of participants, from time of enrollment to study completion. Methods: We reviewed the landmark clinical trials of each of the single-agent chemotherapies specified by the NCCN for use in locally advanced/metastatic breast cancer. We analysed the cardiovascular exclusion criteria, baseline cardiac evaluation as well as cardiac surveillance of patients in each study. We then in

APA, Harvard, Vancouver, ISO, and other styles

37

Suresh, Samyuktha, Solène Huard, Amélie Brisson, et al. "PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer." Cancers 14, no. 2 (2022): 306. http://dx.doi.org/10.3390/cancers14020306.

Full text

Abstract:

Identifying new therapeutic strategies for triple-negative breast cancer (TNBC) patients is a priority as these patients are highly prone to relapse after chemotherapy. Here, we found that protein arginine methyltransferase 1 (PRMT1) is highly expressed in all breast cancer subtypes. PRMT1 depletion decreases cell survival by inducing DNA damage and apoptosis in various breast cancer cell lines. Transcriptomic analysis and chromatin immunoprecipitation revealed that PRMT1 regulates the epidermal growth factor receptor (EGFR) and the Wnt signaling pathways, reported to be activated in TNBC. PRM

APA, Harvard, Vancouver, ISO, and other styles

38

Wang, Yuzhi, Tengfei Bian, Lina Song, et al. "Reducing Chemotherapy-Induced DNA Damage via nAChR-Mediated Redox Reprograming—A New Mechanism for SCLC Chemoresistance Boosted by Nicotine." Cancers 14, no. 9 (2022): 2272. http://dx.doi.org/10.3390/cancers14092272.

Full text

Abstract:

Up to 60% of patients with small cell lung cancer (SCLC) continue to smoke, which is associated with worse clinical outcomes. Platinum-based chemotherapies, in combination with topoisomerase inhibitors, are first-line therapies for SCLC, with rapid chemoresistance as a major barrier. We provided evidence in this study that nicotine and its major metabolite, cotinine, at physiologically relevant concentrations, reduced the efficacy of platinum-based chemotherapies and facilitated chemoresistance in SCLC cells. Mechanistically, nicotine or cotinine reduced chemotherapy-induced DNA damage by modu

APA, Harvard, Vancouver, ISO, and other styles

39

Zhuang, Xinguo, Tracey A. Martin, Fiona Ruge, et al. "Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance." Biomedicines 11, no. 12 (2023): 3136. http://dx.doi.org/10.3390/biomedicines11123136.

Full text

Abstract:

(1) Introduction: Claudin-9 (CLDN9) is a member of the claudin protein family, a critical transmembrane protein family for tight junctions that are implemented in the progression of numerous cancer types. The present study investigated the role that CLDN9, along with the subcoat proteins, Zonula Occludens (ZOs), plays in clinical breast cancer and subsequent impact on drug response of patients. (2) Methods: CLDN9 protein and CLDN9 transcript were determined and correlated with clinical and pathological indicators, together with the status of hormonal receptors. The levels of CLDN9 transcript w

APA, Harvard, Vancouver, ISO, and other styles

40

Chen, Kai, Yingnan Si, Seulhee Kim, Zhuoxin Zhou, Lufang Zhou, and X. Margaret Liu. "Abstract 5326: Targeted extracellular vesicle to deliver combined chemotherapies to treat cancers." Cancer Research 82, no. 12_Supplement (2022): 5326. http://dx.doi.org/10.1158/1538-7445.am2022-5326.

Full text

Abstract:

Abstract Extracellular vesicles (EV), facilitated with cancer-targeted antibody or peptide, have been demonstrated as an effective delivery vehicle of chemotherapy and gene therapy. This study aimed to develop and evaluate a targeted EV to deliver a newly identified natural cytotoxic marine compound verrucarin A (Ver-A) or combination with highly potent microtubule polymerization inhibitor mertansine (DM1). The tumor models, glioblastoma (GBM), triple-negative breast cancer (TNBC) and others, were used to validate the developed targeted therapy. First, the stirred-tank bioreactor-based EV biom

APA, Harvard, Vancouver, ISO, and other styles

41

Molin, Yann, and Jérôme Fayette. "Current chemotherapies for recurrent/metastatic head and neck cancer." Anti-Cancer Drugs 22, no. 7 (2011): 621–25. http://dx.doi.org/10.1097/cad.0b013e3283421f7c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

André, N., D. Barbolosi, F. Billy, et al. "Mathematical model of cancer growth controled by metronomic chemotherapies." ESAIM: Proceedings 41 (December 2013): 77–94. http://dx.doi.org/10.1051/proc/201341004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hieke, K., and A. Grothey. "PCN21 TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY." Value in Health 8, no. 6 (2005): A39—A40. http://dx.doi.org/10.1016/s1098-3015(10)67259-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hansen, Suzanne K., and Loren L. Miller. "Regulatory Strategies for the Development of Adjunctive Cancer Chemotherapies." Drug Information Journal 31, no. 3 (1997): 789–803. http://dx.doi.org/10.1177/009286159703100320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Muggia, Franco M., and Christy A. Russell. "New chemotherapies for ovarian cancer. Systemic and intraperitoneal podophyllotoxins." Cancer 67, S1 (1991): 225–30. http://dx.doi.org/10.1002/1097-0142(19910101)67:1+<225::aid-cncr2820671304>3.0.co;2-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Prouse, Teagan, Mohammad A. Mohammad, Sonali Ghosh, et al. "Pancreatic Cancer and Venous Thromboembolism." International Journal of Molecular Sciences 25, no. 11 (2024): 5661. http://dx.doi.org/10.3390/ijms25115661.

Full text

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, prim

APA, Harvard, Vancouver, ISO, and other styles

47

Muluneh, Benyam, Allison Deal, Maurice D. Alexander, et al. "Patient perspectives on the barriers associated with medication adherence to oral chemotherapy." Journal of Oncology Pharmacy Practice 24, no. 2 (2016): 98–109. http://dx.doi.org/10.1177/1078155216679026.

Full text

Abstract:

Purpose Appropriate use of oral chemotherapy is a challenge for patients and clinicians. The purpose of this study was to analyze cancer patients’ use of oral chemotherapies and identify opportunities to improve adherence. Methods We developed a 30-question survey to address frequency and reasons for reducing/skipping doses; sources of information for oral chemotherapy use; perceived importance of food–drug effects; and ease of understanding labeling directions. Results Ninety-three patients taking oral chemotherapies with chronic myeloid leukemia, renal cell carcinoma, breast cancer, and colo

APA, Harvard, Vancouver, ISO, and other styles

48

Wear, Darcy, Eesha Bhagirath, Arpana Balachandar, Caleb Vegh, and Siyaram Pandey. "Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma." International Journal of Molecular Sciences 24, no. 15 (2023): 12052. http://dx.doi.org/10.3390/ijms241512052.

Full text

Abstract:

Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12–15% of childhood cancer deaths. Although current treatments are relatively efficacious against this cancer, associated adverse effects could be detrimental to growth and development. In contrast, glioblastoma accounts for 52% of brain tumours and has an extremely poor prognosis. Current chemotherapeutics include temozolomide, which has numerous negative side-effects and a low-effective rate. Previous studies have shown the manipulation of autophagy to be a promising method for targeting cancers, including g

APA, Harvard, Vancouver, ISO, and other styles

49

Kirhan, Idris, Huseyin Taskiran, and Ataman Gönel. "Effect of Conventional Chemotherapies on Natural Killer Cell Activity." Current Cancer Therapy Reviews 17, no. 3 (2021): 251–54. http://dx.doi.org/10.2174/1573394717666210223111332.

Full text

Abstract:

Background: The effects of chemotherapeutics agents are considered to influence the immune system and cells due to their myelosuppressive and immunosuppressive functions. Natural killer cells are one of the important components of the innate immune system and have a critical role against tumor cells and infections. Objective: The study was aimed to demonstrate whether conventional chemotherapies had an effect on Natural Killer (NK) cell activity. Methods: Forty-nine adjuvant and 19 first-time metastatic chemotherapy-naïve cancer patients were recruited into the study. Blood samples at pre-chem

APA, Harvard, Vancouver, ISO, and other styles

50

Liu, Jing, Mengxing Liu, Hongxing Zhang, et al. "Exploring cysteine regulation in cancer cell survival with a highly specific “Lock and Key” fluorescent probe for cysteine." Chemical Science 10, no. 43 (2019): 10065–71. http://dx.doi.org/10.1039/c9sc02618e.

Full text

Abstract:

Using a highly specific “lock and key” fluorescent Cys probe, we confirmed that targeting Cys metabolism to deplete intracellular Cys is a more potent strategy to sensitize cancer cells to chemotherapies.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!